Know Cancer

or
forgot password

A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)


Phase 2
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)


Inclusion Criteria:



- Patients who are at least 18 years of age with cancer of the lung and who have had
either no previous treatment or 1 previous treatment for advanced cancer of the lung.
Certain other treatments may also be allowed (prior cytotoxic chemotherapy in the
adjuvant setting)

Exclusion Criteria:

- Patients who have had treatment with any investigational therapy within the past 30
days are not eligible.

- Patients who have had a disease or medical condition that is not controlled will not
be eligible.

- Patients who are pregnant or breastfeeding are not eligible.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy of MK0457 as a 5 day infusion as measured by radiological exams at baseline and after every other cycle of treatment. After 3 post-treatment radiological assessments, response will be measured after every third cycle.

Outcome Time Frame:

5 Days

Safety Issue:

No

Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Merck

Authority:

United States: Food and Drug Administration

Study ID:

2006_008

NCT ID:

NCT00290550

Start Date:

October 2006

Completion Date:

November 2007

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Advanced Non-Small Cell Lung Cancer
  • NSCLC
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location